Immix Biopharma Reports Termination of Richard Graydon

What Happened
Immix Biopharma, Inc. (IMMX) filed an 8-K (Item 8.01) on July 20, 2026, reporting that Richard Graydon was terminated and is no longer with the company effective July 17, 2026. The company stated the departure was for reasons unrelated to his activities at the company and, given his short tenure, management believes the termination will have no material effect on the business.

Key Details

• 8-K filed: July 20, 2026 (Item 8.01).
• Effective date of termination: July 17, 2026.
• Company statement: departure unrelated to Graydon’s activities at the company.
• Management view: due to Graydon’s short tenure, the termination is not expected to be material; no replacement, severance, or further details were disclosed.

Why It Matters
Per the filing, Immix Biopharma characterizes this as a personnel change with no expected material impact on results or operations. For investors, there is no immediate financial or operational action required based on this disclosure; shareholders should watch future filings for any additional leadership updates or disclosures that might affect strategy or results.